home All News open_in_new Full Article

Novo Nordisk comprará Akero Therapeutics por hasta 4.478 millones para hacerse con un fármaco para el MASH

La compañía ha indicado que la adquisición no alterará sus previsiones de beneficios para 2025. Más información: Novo Nordisk cierra el primer semestre con un beneficio de 7.442 millones, un 22% más


today 3 w. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Events
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Politics


ID: 1252247345
Add Watch Country

arrow_drop_down